SPECIAL FEATURES:
Pollen 'pills' could deliver vaccines to soldiers
DARPA-funded researchers are looking into utilizing tiny yet tough pollen shells to create oral vaccines for soldiers while they are in battle.
Thu, Nov 29 2012 at 12:31 PM
Related Topics:
Photo: Shutterstock.com
Sneezing allergy sufferers try to avoid plant pollen like the plague. But U.S. military troops could end up popping vaccine pills made from tiny pollen particles into their mouths.
The idea harnesses the power of pollen's natural engineering — a tough outer shell made from a polymer that could survive the human body's stomach acids and digestive processes. That new project by Texas Tech University has drawn military funding from the U.S. Defense Advanced Research Projects Agency (DARPA).
Oral vaccines skip the pain of a needle injection and don't need trained medical personnel to administer. But researchers have struggled to create vaccine pills that can survive long enough inside the body to properly deliver the vaccine.
Harvinder Gill, a chemical engineer at Texas Tech University, plans to scoop out the pollen's allergy-causing innards and leave just the nonallergenic outer shell. Vaccine could fill the empty shells for troops to ingest.
Gill represents one of the academic researchers who received funding through DARPA's Young Faculty Awards program. His funded project will become part of DARPA's broader efforts to make battlefield medicine both simpler and more effective for troops.
Similar DARPA medical projects include developing miniaturized biochip versions of human body parts and organs for speedier drug testing, as well as creating swarms of tiny sensors that could diagnose or treat soldiers from inside their bodies.
Follow TechNewsDaily on Twitter @TechNewsDaily, or on Facebook.
Related on TechNewsDaily and MNN:
This story was originally written for TechNewsDaily and is reprinted with permission here. Copyright 2012 TechNewsDaily, a TechMediaNetwork company.
You might also like:
Sign in with one of these accounts to add your comment.

Email











Join the conversation